- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Moderna seeks USFDA nod for COVID booster tailored against Omicron subvariants
The submission also includes clinical trial data for its BA.1 Omicron-targeting bivalent booster candidate, which was last week cleared in Britain.
New Delhi: Moderna Inc on Tuesday sought U.S. authorization for its COVID-19 booster shot tailored against the BA.4 and BA.5 subvariants of Omicron and said if cleared it would be ready to deliver the doses in September.
Its application with the U.S. Food and Drug Administration (USFDA) is based on pre-clinical data for the so-called bivalent dose that contains the dominant BA.4/BA.5 variants along with the original coronavirus strain.
Moderna said a mid-to-late stage trial for the vaccine is under way.
The submission also includes clinical trial data for its BA.1 Omicron-targeting bivalent booster candidate, which was last week cleared in Britain.
Moderna's announcement comes a day after rival Pfizer Inc and German partner BioNTech sought U.S. authorization for their vaccine booster retooled to target the BA.4/BA.5 subvariants of Omicron.
Pfizer's application is for emergency use among 12 years and older, while Moderna has sought authorization for use among people aged 18 and above.
Pfizer said the doses would be ready to be shipped immediately after the regulatory clearance. Moderna too has been ramping up the production of the BA.4 and BA.5 targeting vaccine to be ready for delivery next month.
Countries including the United States, Britain and EU members have been preparing for vaccination campaigns in the fall season to protect against future surges.
The FDA had in June asked vaccine makers to tailor shots to target the two dominant subvariants and said it would not require studies testing the shots in humans for authorization, similar to how annual changes to flu vaccines are handled.
In human and pre-clinical trials, Moderna's two booster shots against the BA.1 as well as BA.4 and BA.5 subvariants showed strong neutralizing activity compared to the booster against the original coronavirus strain, the company said.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751